• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.

作者信息

Levi Shai, Bronstein Yotam, Goldschmidt Neta, Morabito Fortunato, Ziv-Baran Tomer, Del Poeta Giovanni, Bairey Osnat, Del Principe Maria Ilaria, Fineman Riva, Mauro Francesca Romana, Gutwein Odit, Reda Gianluigi, Ruchlemer Rosa, Sportoletti Paolo, Laurenti Luca, Shvidel Lev, Coscia Marta, Tadmor Tamar, Varettoni Marzia, Aviv Ariel, Murru Roberta, Braester Andrei, Chiarenza Annalisa, Visentin Andrea, Pietrasanta Daniela, Loseto Giacomo, Zucchetto Antonella, Bomben Riccardo, Olivieri Jacopo, Neri Antonio, Rossi Davide, Gaidano Gianluca, Trentin Livio, Foà Robin, Cuneo Antonio, Perry Chava, Gattei Valter, Gentile Massimo, Herishanu Yair

机构信息

Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.

出版信息

Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.

DOI:10.1002/ajh.26779
PMID:36349541
Abstract
摘要

相似文献

1
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.一线依鲁替尼与氟达拉滨、环磷酰胺和利妥昔单抗治疗慢性淋巴细胞白血病患者的疗效：一项回顾性多中心“真实世界”研究。
Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
2
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.伊布替尼联合氟达拉滨、环磷酰胺和利妥昔单抗（iFCR）作为伴有或不伴有TP53异常的慢性淋巴细胞白血病/小淋巴细胞白血病的初始治疗：一项中国队列的前瞻性真实世界研究
Blood Cancer J. 2023 Aug 9;13(1):121. doi: 10.1038/s41408-023-00890-y.
3
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).在接受一线氟达拉滨、环磷酰胺和强化剂量奥法木单抗（FCO2）治疗的IGHV突变型慢性淋巴细胞白血病的年轻健康患者中，微小残留病缓解率很高。
Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.
4
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.在既往未接受治疗的慢性淋巴细胞白血病患者中进行的一项随机IIB期试验的临床疗效和成本效益结果，该试验比较氟达拉滨、环磷酰胺和利妥昔单抗与氟达拉滨、环磷酰胺、米托蒽醌和低剂量利妥昔单抗：慢性淋巴细胞白血病中减量化利妥昔单抗联合化疗（ARCTIC）试验。
Health Technol Assess. 2017 May;21(28):1-374. doi: 10.3310/hta21280.
5
Ibrutinib and rituximab for chronic lymphocytic leukaemia.依鲁替尼和利妥昔单抗治疗慢性淋巴细胞白血病
Lancet Oncol. 2019 Sep;20(9):e471. doi: 10.1016/S1470-2045(19)30528-5. Epub 2019 Aug 8.
6
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.利妥昔单抗联合氟达拉滨和环磷酰胺或其他药物治疗慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132.
7
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.美国商业保险覆盖的年轻慢性淋巴细胞白血病患者的真实世界治疗模式、不良事件、资源利用和成本：一项回顾性队列研究。
Adv Ther. 2020 Jul;37(7):3129-3148. doi: 10.1007/s12325-020-01350-w. Epub 2020 May 12.
8
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.氟达拉滨-环磷酰胺-利妥昔单抗方案一线治疗临床试验以外的慢性淋巴细胞白血病的疗效和安全性：以色列慢性淋巴细胞白血病研究组的经验
Haematologica. 2015 May;100(5):662-9. doi: 10.3324/haematol.2014.115808. Epub 2015 Feb 6.
9
[Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].利妥昔单抗联合氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病的临床疗效与安全性
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):25-9. doi: 10.7534/j.issn.1009-2137.2016.01.005.
10
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和利妥昔单抗治疗未经治疗的慢性淋巴细胞白血病的 II 期日本临床试验。
Jpn J Clin Oncol. 2021 Mar 3;51(3):408-415. doi: 10.1093/jjco/hyaa215.